Autoinjectors Market Worth $ 104.9 Billion : Rising Incidence Of Anaphylaxis

 Market growth is largely driven by the growing prevalence of targeted therapies, the rising incidence of anaphylaxis, rising preference for self-administration of drugs, usability advantages, the increasing number of regulatory approvals, the availability of generic versions of autoinjectors, favorable reimbursements and government support, and technological advancements. The patent expiry of biologics is also expected to provide growth opportunities for players in the market.

[180 Pages Report] The global autoinjectors market is projected to reach USD 104.9 billion by 2025 from USD 46.0 billion in 2020, at a CAGR of 17.9% from 2020 to 2025.

Market Dynamics

• Growing prevalence of targeted therapies
• Rising incidence of anaphylaxis
• Increasing number of regulatory approvals
• Availability of generic versions of autoinjectors
• Favorable reimbursements and government support
• Ease of use increasing the preference for self-administration

COVID-19 Impact on The Autoinjectors Market

The COVID-19 pandemic has resulted in a global healthcare crisis, causing a shift in healthcare delivery in most regions. Most non-essential procedures and in-hospital therapies were deferred in the first half of 2020 to prevent the spread of the infection and ease the toll on healthcare infrastructure. According to researchers at Indiana University, healthcare visits decreased by around 40% in the first six weeks of the pandemic in the US, from early March to mid-April. After restrictions were eased, there has been an overall decline in patients delaying seeking care and treatment in healthcare settings.

In summary, the COVID-19 pandemic has been accelerating the trend of self-injection, empowering patients to have more involvement and control over their treatment. Newer technologies in the autoinjectors market have encouraged this trend, as they allow better management of injection speed, injection site pain, and treatment anxiety.

Download PDF Brochure @  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=173991724 

Opportunity: Need to limit patient visits and physical contact

The current COVID-19 pandemic has resulted in the implementation of a fresh set of protocols that aim to reduce patient visits to hospitals and clinics in non-emergency conditions to prevent both the transmission of the virus as much as make sure healthcare institutions are not overwhelmed. In this situation, the preference for home-use autoinjectors has risen among patients suffering from chronic illnesses and allergies. This also protects vulnerable high-risk populations from exposure to the virus during hospital visits.

Autoinjectors are being developed to support increased viscosity and concentrations of drugs to reduce administration frequency, thus increasing adherence to recommended drug protocols. These factors present an opportunity for the growth of the autoinjectors market in the current COVID-19 scenario.

The geographical regions mapped in the report are:

Geographically, the autoinjectors market is segmented into North America, Europe, the Asia Pacific, Latin America, and Middle East & Africa. Growth in the Asia Pacific market is majorly driven by the large diabetes population and increasing healthcare expenditure which has drawn a number of major autoinjector device manufacturers to this region. These companies are increasing their presence in the Asia Pacific market through several approaches, such as establishing sales offices and partnering with local pharmaceutical companies

Request for sample pages @   https://www.marketsandmarkets.com/requestsampleNew.asp?id=173991724 

Autoinjectors Market | Availability of Generic Versions of Autoinjectors

 According to the new market research report “Autoinjectors Market by Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Cardiovascular diseases, Psoriasis, Migraine), Type (Disposable, and Reusable), End Users (Homecare, and Hospitals) - Global Forecast to 2023", published by MarketsandMarkets™, The global Autoinjectors Market is projected to reach USD 85.31 billion by 2023 from an estimated USD 28.91 billion in 2018, at a CAGR of 24.2% during the forecast period (2018-2023).

The key factors driving the growth of this market include the growing prevalence of targeted therapies such as rheumatoid arthritis and multiple sclerosis, rising incidence of anaphylaxis, and increasing number of regulatory approvals.

Get Sample Report @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=173991724

                     

The patent expiry of biologics in the coming years is also expected to provide growth opportunities for players in the autoinjectors market

Autoinjectors are used to self-administer drugs for the treatment of various diseases and conditions, such as rheumatoid arthritis, multiple sclerosis, diabetes, and anaphylaxis. Autoinjectors are easy to use, portable, and improve dosing accuracy, making them one of the most popular methods for the self-administration of drugs.

Disposable autoinjectors segment is expected to grow at the highest CAGR during the forecast period.
disposable autoinjectors are the most-preferred autoinjectors due to their ease of use and the presence of a built-in glass syringe (eliminates the need for manually loading the glass syringe), which makes it more convenient for patients with reduced dexterity or visual impairments.

Critical questions the report answers:

⏩ Which are the most significant revenue-generating regions for the market?
⏩ What are the significant upcoming trends in the market?
⏩ How will the market drivers, restraints, and future opportunities affect the market dynamics?
⏩ Which end-user segment is expected to witness maximum growth opportunities during the forecast period?

North America to witness the highest market growth during the forecast period
The large share of the North American autoinjectors market can primarily be attributed to the rising prevalence of autoimmune and chronic diseases, increasing prevalence of anaphylaxis, and the increasing number of FDA approvals in the region.

Download PDF Brochure @https://www.marketsandmarkets.com/requestsampleNew.asp?id=173991724

Autoinjectors Market: Global Industry Analysis, Trends, Market Size, and Forecasts

Autoinjectors are used to self-administer drugs for the treatment of various diseases and conditions, such as rheumatoid arthritis, multiple sclerosis, diabetes, and anaphylaxis. Autoinjectors are easy to use, portable, and improve dosing accuracy, making them one of the most popular methods for the self-administration of drugs.

How much is the Autoinjectors Market worth?

The autoinjectors market is projected to reach USD 85.31 billion by 2023 from an estimated USD 28.91 billion in 2018, at a CAGR of 24.2%. Growth in the global autoinjectors market is mainly driven by factors such as the growing prevalence of targeted therapies, the rising incidence of anaphylaxis, the increasing number of regulatory approvals, the availability of generic versions of autoinjectors, favorable reimbursements and government support, and technological advancements in autoinjector devices.

The patent expiry of biologics in the coming years is also expected to provide growth opportunities for players in the autoinjectors market

Download PDF Brochure @https://www.marketsandmarkets.com/requestsampleNew.asp?id=173991724

Disposable autoinjectors segment is expected to grow at the highest CAGR during the forecast period.

isposable autoinjectors are the most-preferred autoinjectors due to their ease of use and the presence of a built-in glass syringe (eliminates the need for manually loading the glass syringe), which makes it more convenient for patients with reduced dexterity or visual impairments.

The rheumatoid arthritis segment to account for the largest share of the autoinjectors market.

The demand for Disposable Autoinjectors for this therapy segment is fueled by the increasing incidence of RA across the globe. According to the CDC, an estimated 43.7 million adults (22.7% of the total population) in the US annually are affected by some form of arthritis, RA, gout, lupus, or fibromyalgia. By 2040, an estimated 78 million (26%) US adults aged 18 years or older are projected to have doctor-diagnosed arthritis.

Request for Sample Pages @https://www.marketsandmarkets.com/requestsampleNew.asp?id=17399172

Regional Growth, Development and Demand Analysis:

North America to witness the highest market growth during the forecast period
The large share of the North American Disposable Autoinjectors can primarily be attributed to the rising prevalence of autoimmune and chronic diseases, increasing prevalence of anaphylaxis, and the increasing number of FDA approvals in the region

Critical questions the report answers:

⏩ Which are the most significant revenue-generating regions for the market?
⏩ What are the significant upcoming trends in the market?
⏩ How will the market drivers, restraints, and future opportunities affect the market dynamics?
⏩ Which end-user segment is expected to witness maximum growth opportunities during the forecast period?

To speak to our analyst for a discussion on the above findings, click Speak to Analyst @https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=173991724

Autoinjectors Market worth $85.31 billion by 2023 – Exclusive Report by MarketsandMarkets™

 According to the new market research report “Particle Therapy Market by Type (Heavy Ion, Proton Therapy), Products (Cyclotron, Synchrotron, Synchrocyclotron), Services, System (Single-room, Multi-room), Cancer Type (Pediatric, Prostate, Breast), Application (Treatment, Research) - Forecast to 2023", published by MarketsandMarkets™, The global particle therapy market is projected to reach USD 1,349 million by 2023 from USD 865 million in 2018, at a CAGR of 9.3%.

Access Free Sample Research Copy :https://www.marketsandmarkets.com/requestsampleNew.asp?id=173991724

                                

This market is segmented into disposable and reusable autoinjectors. The disposable autoinjectors segment is expected to account for the largest market share in 2017. This can primarily be attributed to their ease of use and the presence of a built-in glass syringe which makes it more convenient for patients with reduced dexterity or visual impairments.

Autoinjectors are easy-to-handle and cost-effective medical devices that can be used by patients, caregivers, and even untrained personnel to deliver a dose of a particular drug. Autoinjectors are used by patients to manage autoimmune diseases and chronic diseases. They are used for a wide range of indications such as rheumatoid arthritis, multiple sclerosis, diabetes, and anaphylaxis.

Download the PDF brochure@https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=12809137

Preference for alternative drug delivery modes such as oral diabetic agents, oral insulin, and epinephrine nasal sprays is a major factor restraining the growth of the market. Traditional injectables are invasive and painful modes of drug delivery owing to which patients and care providers are increasingly focusing on alternative routes of drug delivery, such as oral, topical, and nasal routes.

Among the various routes of drug delivery, the oral route is the most preferred as it is easy to use, convenient, cost-effective, safe, and acceptable. Moreover, the introduction of needle-free drug delivery devices such as jet injectors also restricts the growth of the autoinjectors market.

Growth in the particle therapy market is primarily driven by factors such as the various advantages offered by particle therapy over photon therapy, growing global prevalence of cancer, increasing adoption of particle therapy in clinical trials, and the increasing number of particle therapy centers worldwide.

Synchrotrons are used to accelerate both protons and heavy ions such as carbon and hydrogen. The growth of the synchrotrons segment is attributed to factors such as the increasing number of research activities as well as the increasing investments in the development of synchrotron facilities.

Request Bundle Reports @ https://www.marketsandmarkets.com/RequestBundleReport.asp?id=12809137

Ion Beam Applications SA (Belgium), Varian Medical Systems, Inc. (US), and Hitachi, Ltd. (Japan) are the major players operating in the particle therapy market. Other players in this market include Provision Healthcare (US), Mevion Medical Systems, Inc. (US), Sumitomo Heavy Industries, Ltd. (Japan), Optivus Proton Therapy, Inc. (US), ProTom International, Inc. (US), Advanced Oncotherapy Plc. (UK), and Danfysik A/S (Denmark).
By application, treatment applications are expected to be the largest contributor to the particle therapy market

The introduction of small footprint single-room particle therapy centers is further promoting the adoption of proton therapy for the treatment of cancer in small-scale hospitals. Factors driving the growth of the treatment applications segment include the growing number of cancer patients globally, increasing government initiatives (aimed at equipping or upgrading hospitals with newer and advanced radiotherapy systems), and the increasing availability of funding for the adoption of advanced cancer treatment technologies.

Autoinjectors Market Trends Estimates High Demand by 2023

According to the new market research report “Autoinjectors Market by Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Cardiovascular diseases, Psoriasis, Migraine), Type (Disposable, and Reusable), End Users (Homecare, and Hospitals) - Global Forecast to 2023", published by MarketsandMarkets™, The global Autoinjectors Market is projected to reach USD 85.31 billion by 2023 from an estimated USD 28.91 billion in 2018, at a CAGR of 24.2% during the forecast period (2018-2023).

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=173991724

The key factors driving the growth of this market include the growing prevalence of targeted therapies such as rheumatoid arthritis and multiple sclerosis, rising incidence of anaphylaxis, and increasing number of regulatory approvals.

Use of autoinjectors in the treatment of rheumatoid arthritis drives the global autoinjectors market

Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory autoimmune disease that affects connective tissues. It causes joints to swell and can result in pain, stiffness, and progressive loss of function. According to the CDC, an estimated 43.7 million adults (22.7% of the total population) in the US annually are affected by some form of arthritis, RA, gout, lupus, or fibromyalgia.

Global Autoinjectors Market Segmentation:
+ On the basis of type, the market is segmented into disposable and reusable autoinjectors. The disposable autoinjectors segment is expected to account for the largest market share in 2017. This can primarily be attributed to their ease of use and the presence of a built-in glass syringe which makes it more convenient for patients with reduced dexterity or visual impairments.

+ On the basis of therapy, the market is segmented into rheumatoid arthritis, multiple sclerosis, anaphylaxis, diabetes, migraine, and other therapies (includes cardiovascular diseases, migraine treatment, anemia, and progesterone therapy). The rheumatoid arthritis segment accounted for the largest share of the market in 2017. The large share of this segment is mainly attributed to the high prevalence of rheumatoid arthritis across the globe.

+ On the basis of end users, the market is segmented into home care settings and hospitals & clinics. The home care settings segment commanded the largest share of the market in 2017. The large share of this end-user segment can primarily be attributed to the rapid growth in the geriatric population across the globe and the growing need for cost-effective drug administration.

Get Expert Analysis and Insights of Global Market | Request Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=173991724

What Drives the Market?
1. Growing prevalence of targeted therapies
2. Rising incidence of anaphylaxis
3. Increasing number of regulatory approvals
4. Availability of generic versions of autoinjectors

Geographical Growth Analysis:

In 2018, North America is expected to account for the largest share of the autoinjectors market, followed by Europe. Factors such as increasing geriatric population in Canada, increasing FDA approvals, rising prevalence of anaphylaxis in the US, and rising prevalence of autoimmune and chronic diseases in the US and Canada are contributing to the large share of North America.

Key Players and Strategies Adopted by Them:

The key players in the global autoinjectors market are Abbvie (US), Amgen (US), Teva (Israel), Biogen (US), Eli Lilly (US), and Mylan (US). The other prominent players in the market are J&J (US), Novartis (Switzerland), Bayer (Germany), Merck (Germany), Biogen (US), Ypsomed (Switzerland), SHL Group (Taiwan) Becton, Dickinson and Company (US), Owen Mumford (UK), Novartis (Switzerland), and Haselmeier (Switzerland).

Autoinjectors Market Trends Estimates High Demand by 2023

According to the new market research report “Autoinjectors Market by Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Cardiovascular diseases, Psoriasis, Migraine), Type (Disposable, and Reusable), End Users (Homecare, and Hospitals) - Global Forecast to 2023", published by MarketsandMarkets™, The global Autoinjectors Market is projected to reach USD 85.31 billion by 2023 from an estimated USD 28.91 billion in 2018, at a CAGR of 24.2% during the forecast period (2018-2023).

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=173991724

The key factors driving the growth of this market include the growing prevalence of targeted therapies such as rheumatoid arthritis and multiple sclerosis, rising incidence of anaphylaxis, and increasing number of regulatory approvals.

Use of autoinjectors in the treatment of rheumatoid arthritis drives the global autoinjectors market

Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory autoimmune disease that affects connective tissues. It causes joints to swell and can result in pain, stiffness, and progressive loss of function. According to the CDC, an estimated 43.7 million adults (22.7% of the total population) in the US annually are affected by some form of arthritis, RA, gout, lupus, or fibromyalgia.

Global Autoinjectors Market Segmentation:

+ On the basis of type, the market is segmented into disposable and reusable autoinjectors. The disposable autoinjectors segment is expected to account for the largest market share in 2017. This can primarily be attributed to their ease of use and the presence of a built-in glass syringe which makes it more convenient for patients with reduced dexterity or visual impairments.

+ On the basis of therapy, the market is segmented into rheumatoid arthritis, multiple sclerosis, anaphylaxis, diabetes, migraine, and other therapies (includes cardiovascular diseases, migraine treatment, anemia, and progesterone therapy). The rheumatoid arthritis segment accounted for the largest share of the market in 2017. The large share of this segment is mainly attributed to the high prevalence of rheumatoid arthritis across the globe.

+ On the basis of end users, the market is segmented into home care settings and hospitals & clinics. The home care settings segment commanded the largest share of the market in 2017. The large share of this end-user segment can primarily be attributed to the rapid growth in the geriatric population across the globe and the growing need for cost-effective drug administration.

Get Expert Analysis and Insights of Global Market | Request Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=173991724

What Drives the Market?
1. Growing prevalence of targeted therapies
2. Rising incidence of anaphylaxis
3. Increasing number of regulatory approvals
4. Availability of generic versions of autoinjectors

Geographical Growth Analysis:
In 2018, North America is expected to account for the largest share of the autoinjectors market, followed by Europe. Factors such as increasing geriatric population in Canada, increasing FDA approvals, rising prevalence of anaphylaxis in the US, and rising prevalence of autoimmune and chronic diseases in the US and Canada are contributing to the large share of North America.

Key Players and Strategies Adopted by Them:

The key players in the global autoinjectors market are Abbvie (US), Amgen (US), Teva (Israel), Biogen (US), Eli Lilly (US), and Mylan (US). The other prominent players in the market are J&J (US), Novartis (Switzerland), Bayer (Germany), Merck (Germany), Biogen (US), Ypsomed (Switzerland), SHL Group (Taiwan) Becton, Dickinson and Company (US), Owen Mumford (UK), Novartis (Switzerland), and Haselmeier (Switzerland).